Subgroup analysis in RAISE: A randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression

Annals of Oncology

Volumn 27, Issue 11, 2016, Pages 2082-2089

  Obermannová, Radka ^a   Van Cutsem, E ^b   Yoshino, T ^c   Bodoky, G ^d   Prausova J ^e   Garcia Carbonero, R ^f   Ciuleanu, T ^g   Garcia Alfonso, P ^h   Portnoy, D ⁱ   Cohn, A ^j   Yamazaki, K ^k   Clingan, P ^l   Lonardi, S ^m   Kim, T W ⁿ   Yang, L ^o   Nasroulah, F ^o   Tabernero, J ^p  

^a MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^d Szent Laszlo Hospital   (Hungary)

^e CHARLES UNIVERSITY   (Czech Republic)

^f HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^g THE ONCOLOGY INSTITUTE PROF DR ION CHIRICUTA   (Romania)

^h HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

ⁱ UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^j Rocky Mountain Cancer Center   (United States)

^k SHIZUOKA CANCER CENTER   (Japan)

^l Southern Medical Day Care Centre   (Australia)

^m VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

ⁿ University of Ulsan College of Medicine   (South Korea)

^o ELI LILLY AND COMPANY   (United States)

^p HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

more..

Author keywords

CRC; Metastatic colorectal carcinoma; Phase III clinical trial; RAISE; Ramucirumab; VEGFR 2

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; PLACEBO; RAMUCIRUMAB; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; KRAS PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PROTEIN P21;

ABDOMINAL PAIN; ADULT; AGE DISTRIBUTION; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER GROWTH; COLORECTAL CARCINOMA; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EPISTAXIS; FATIGUE; FEMALE; HUMAN; HYPERTENSION; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CARCINOMA; MUTATIONAL ANALYSIS; NAUSEA; NEUTROPENIA; ONCOGENE K RAS; ONCOLOGICAL PARAMETERS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; TIME TO PROGRESSION; VOMITING; WILD TYPE; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; GENETICS; KAPLAN MEIER METHOD; METASTASIS; MIDDLE AGED; MUTATION; PATHOLOGY;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS P21(RAS);

EID: 85011379788     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw402     Document Type: Article

References (18)

1. Van Cutsem E, Cervantes A, Nordlinger B, Arnold D. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25(Suppl. 3): iii1-iii9
2. Surveillance, Epidemiology, and End Results Program. SEER stat fact sheets: colon and rectum cancer. http://seer.cancer.gov/statfacts/html/colorect.html (22 February 2016, date last accessed)
3. National Comprehensive Care Network. Clinical practice guidelines in oncology (NCCN guidelines®): colon cancer; rectal cancer. Version 2. 2015. http://www. nccn.org/professionals/physician_gls/pdf/colon.pdf; http://www.nccn.org/ professionals/physician_gls/pdf/rectal.pdf. (20 November 2015, date last accessed)
4. Leung DW, Cachianes G, Kuang WJ et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306-1309
5. Tugues S, Koch S, Gualandi L et al. Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer. Mol Aspects Med 2011; 32: 88-111
6. Amini A, Masoumi Moghaddam S, Morris DL, Pourgholami MH. The critical role of vascular endothelial growth factor in tumor angiogenesis. Curr Cancer Drug Targets 2012; 12: 23-43
7. Spratlin JL, Cohen RB, Eadens M et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 2010; 28: 780-787
8. Tabernero J, Yoshino T, Cohn AL et al. Ramucirumab versus placebo in combination with second line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 2015; 16: 499-508
9. Yen LC, Uen YH, Wu DC et al. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab. Ann Surg 2010; 251: 254-260
10. Kuboki Y, Mizunuma N, Ozaka M et al. Grade 3/4 neutropenia is a limiting factor in second-line FOLFIRI following FOLFOX4 failure in elderly patients with metastatic colorectal cancer. Oncol Lett 2011; 2: 493-498
11. Shitara K, Matsuo K, Yokota T et al. Prognostic factors for metastatic colorectal cancer patients undergoing irinotecan-based second-line chemotherapy. Gastrointest Cancer Res 2011; 4: 168-172
12. Kubicka S, Greil R, André T et al. Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings. Ann Oncol 2013; 24: 2342-2349
13. Therkildsen C, Bergmann TK, Henrichsen-Schnack T et al. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: a systematic review and meta-analysis. Acta Oncol 2014; 3: 852-864
14. Bennouna J, Sastre J, Arnold D et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013; 14: 29-37
15. Souglakos J, Pallis A, Kakolyris S. Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: a phase II trial. Oncology 2005; 69: 384-390
16. Sastre J, Marcuello E, Masutti B et al. Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer. J Clin Oncol 2005; 23: 3545-3551
17. Goldberg RM, Tabah-Fisch I, Bleiberg H et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 2006; 24: 4085-4091
18. Sehl M, Sawhney R, Naeim A. Physiologic aspects of aging: impact on cancer management and decision making, part II. Cancer J 2005; 11: 461-473